In This Section

Program

Now in the second year, this exciting event is expected to draw 750-1,000 attendees – venture capitalists, investment bankers, biotech and pharmaceutical scientific and business leaders, and academics interested in oncology drug development and entrepreneurship. Once again, Spotlight Sessions will feature talks from AACR’s leading corporate partners who will discuss their early oncology pipelines, research investment strategies, and unique approaches to innovation within their organizations.

This is the must-attend event for the oncology drug development and investment communities. This year’s meeting will feature six (6) talks from the biotech community selected from a competitive application process, panel discussion sessions, private meeting spaces, and extended space for informal networking through the center.

All sessions and events will be held at the McCormick Place West Building unless noted below. This event will be live-streamed for virtual participation. There will be no on-demand viewing or access to materials after the event.

* schedule and speakers subject to change

platinum supporter

Thursday, April 24

Registration and Networking Breakfast

7:30-9 a.m. | W190 and W194

Welcome

9-9:15 a.m. | W196

Spotlight Session 1: Bristol Myers Squibb

9:15-10 a.m. | W196

  • Michael Pourdehnad, Senior Vice President, Head of Early Clinical Development, Hematology, Oncology and Cell Therapy

Break

10-10:15 a.m. | W196 Foyer

Spotlight Session 2: Pfizer

10:15-11 a.m. | W196

  • Megan O’Meara, Interim Chief Development Officer and Head of Early Stage Development, Pfizer Oncology

Break

11-11:15 a.m. | W196 Foyer

Spotlight Session 3: Johnson & Johnson Innovative Medicine

11:15 a.m.-12 p.m. | W196

  • Yusri A. Elsayed, Senior Vice President, Head of Oncology R&D

Networking Lunch

12-1:30 p.m. | W190 and W194

Concurrent Panel discussions a-b

12:15-1:15 p.m.

CONCURRENT SESSION A: NEXT GENERATION BISPECIFICS

W196 | Moderator: Andrew Berens, Leerink Partners

  • Craig Gibbs, AsherBio
  • Jeff Infante, Johnson & Johnson Innovative Medicine
  • Bill Lundberg, Merus
  • Additional panelists to be announced

CONCURRENT SESSION B: T CELL ENGAGERS

W192 | Moderator: Daina Graybosch, Leerink Partners

  • Ken Galbraith, Zymeworks
  • Martin Lehr, Context Therapeutics
  • Additional panelists to be announced

Spotlight Session 4: Bayer Pharmaceuticals

1:30-2:15 p.m. | W196

  • Dominik Ruettinger, Global Head Research and Early Development Oncology

Break

2:15-2:30 p.m. | W196 Foyer

Spotlight Session 5: AstraZeneca

2:30-3:15 p.m. | W196

  • Susan M. Galbraith, Executive Vice-President, Oncology Research & Development

Break

3:15-3:30 p.m. | W196 Foyer

Spotlight Session 6: Eli lilly & company

3:30-4:15 p.m. | W196

  • Arjun Balar, Senior Vice President, Global Clinical Development

Break

4:15-4:30 p.m. | W196 Foyer

showcase sessions 1-2

4:30-5:30 p.m.

SHOWCASE SESSION 1 | W196

  • 4:35 p.m. | Crossbow Therapeutics
    Briggs Morrison, Chief Executive Officer
  • 4:50 p.m. | Aethon Therapeutics
    Sean Toenjes, Executive Director of Chemistry & Innovation
  • 5:05 p.m. | Zymeworks
    Lucas Donigian, Vice President, Business & Commercial Development

SHOWCASE SESSION 2 | W192

  • 4:35 p.m. | CatenaBio
    Saurabh Johri, Chief Business Officer
  • 4:50 p.m. | Innate Pharma
    Jonathan Dickinson, Chairman of the Executive Board, Chief Executive Officer
  • 5:05 p.m. | OncoC4
    Pan Pan, Senior Vice President, Head of Business Development

Break

5:30-5:45 p.m. | W196 Foyer

Concurrent Panel discussions c-d

5:45-6:45 p.m.

CONCURRENT SESSION C: DRUGGING THE UNDRUGGABLE/TRANSCRIPTION FACTORS

W196 | Moderator: Rami Rahal, MPM BioImpact

  • Nick Glover, MycRX
  • Peter Smith, Remix Therapeutics
  • Liron Bar-Peled, Massachusetts General Hospital

CONCURRENT SESSION D: TO BE ANNOUNCED

W192 | Moderator: To be announced

  • Panelists to be announced

Reception

7-9 p.m. | Regency Ballroom, Hyatt Regency McCormick Place

Friday, April 25

Registration and Networking Breakfast

7-8 a.m. | W190 and W194

Spotlight Session 7: Novartis

8-8:45 a.m. | W196

  • Dushen Chetty, Global Head of Oncology, Development       

Break

8:45-9 a.m. | W196 Foyer

Spotlight Session 8: Genentech/roche

9-9:45 a.m. | W196

  • Levi A. Garraway, Executive Vice President, Head of Product Development, and Chief Medical Officer

Break

9:45-10 a.m. | W196 Foyer

Spotlight Session 9: merck

10-10:45 a.m. | W196

  • Jane A. Healy, Vice President and Head of Oncology Early Development

Break

10:45-11 a.m. | W196 Foyer

Spotlight Session 10: Gilead

11-11:45 a.m. | W196

  • Flavius Martin, Executive Vice President

Break

11:45 a.m.-12 p.m. | W196 Foyer

Spotlight Session 11: Amgen

12-12:45 p.m. | W196

  • Jean-Charles Soria, Senior Vice President of Oncology
  • Erin Denny, Executive Director, External R&D, Inflammation, Oncology

Closing Keynote / Fireside Chat

12:45-1:45 p.m. | W196

Closing Remarks

1:45-2 p.m. | W196

lunch available

2-3 p.m. | W190 and W194